-Bloomberg
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $18 to $8.
Fed’s Brainard Says If Russia Conflict Persists, Risks To Inflation Are Higher
-Bloomberg
Related Posts
Markel Earnings Conference Call Is Coming Up, Here’s What You Need To Know
Markel (NYSE:MKL) will host a conference call at 09:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results.
How to Attend Markel (MKL) Conference Call
Follow this link to access the live webcast.
Keybanc Maintains Overweight on Revolve Gr, Raises Price Target to $70
Keybanc analyst Edward Yruma maintains Revolve Gr (NYSE:RVLV) with a Overweight and raises the price target from $58 to $70.